@prefix this: . @prefix sub: . @prefix np: . @prefix dct: . @prefix rdf: . @prefix nt: . @prefix xsd: . @prefix rdfs: . @prefix orcid: . @prefix bl: . @prefix nkg: . @prefix prov: . @prefix npx: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { bl:category bl:Disease . sub:association rdf:object ; rdf:predicate bl:treats; rdf:subject ; a rdf:Statement; rdfs:label "Off-label (non-FDA-approved) uses for Lorazepam include rapid tranquilization of the agitated patient, alcohol withdrawal delirium, alcohol withdrawal syndrome, insomnia, panic disorder, delirium, chemotherapy-associated anticipatory nausea and vomiting (adjunct or breakthrough), as well as psychogenic catatonia."; bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation; bl:has_population_context sub:cohort; bl:provided_by ; bl:publications ; bl:relation nkg:OffLabelIndication . sub:cohort rdfs:label "adults"; bl:category bl:Cohort . bl:category bl:Drug . } sub:provenance { sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 . } sub:pubinfo { sub:sig npx:hasAlgorithm "RSA"; npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB"; npx:hasSignature "VwrBp3B/rNl0vOuLjk3M4B9dvXPrL1sD1ynq1TFmcVJ2bqOt0e6HQhm1zTjh46s6ZHiRD+qy4AmWHatbnQaQKQ6JbGYMtI2a19KRshGf3mTIBdOVk8932cCp9X2CdVST8uFwO14dG5opGEyOD5Tq1SEN5p86MR2nW1pHwb6pwUI="; npx:hasSignatureTarget this: . this: dct:created "2021-05-01T09:59:24.001+02:00"^^xsd:dateTime; dct:creator orcid:0000-0002-1468-3557; nt:wasCreatedFromProvenanceTemplate ; nt:wasCreatedFromPubinfoTemplate ; nt:wasCreatedFromTemplate . }